This extensive clinical practice guideline from the Endocrine Society provides evidence-based recommendations on vitamin D use and testing for disease risk reduction across various populations. It addresses questions regarding empiric supplementation versus no supplementation and routine 25(OH)D testing versus no testing for different age groups, pregnant individuals, and those with specific conditions like prediabetes, dark complexion, and obesity. The guideline emphasizes evaluating the certainty of evidence using the GRADE methodology and considers factors like patient values, costs, feasibility, and health equity. Ultimately, it aims to offer clarity on optimal vitamin D intake and the role of testing in individuals without established vitamin D deficiencies.

Source: The Journal of Clinical Endocrinology & Metabolism, 2024, 109, 1907–1947

https://doi.org/10.1210/clinem/dgae290

Advance access publication 3 June 2024

Clinical Practice Guideline